Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Bajor

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2012
Rehabilitation for oncogene addiction: role of immunity in cellular sobrietyDavid L Bajor, Robert H Vonderheide
Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2016
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after ChemotherapyKatelyn T Byrne, Nathan H Leisenring, David L Bajor, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|October 2, 2020
A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissuesYicheng Chen, Yiqing Zhao, David L Bajor, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
CD40 immunotherapy for pancreatic cancerRobert H Vonderheide, David L Bajor, Rafael Winograd, et al.
JCO Oncology Practice|January 12, 2021
Videoconference Intervention for Distance Caregivers of Patients With Cancer: A Randomized Controlled TrialSara L Douglas, Polly Mazanec, Amy R Lipson, et al.
Journal of Gastrointestinal Oncology|July 23, 2021
A pilot study of a low glycemic load diet in patients with stage I-III colorectal cancerMichelle Treasure, Alicia Thomas, Stephen Ganocy, et al.
Oncotarget|October 5, 2020
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?Erryk S Katayama, Jonathan J Hue, David L Bajor, et al.
Nature Communications|September 16, 2016
Metastatic progression is associated with dynamic changes in the local microenvironmentNicole M Aiello, David L Bajor, Robert J Norgard, et al.
Cancer Immunology Research|September 26, 2014
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanomaDavid L Bajor, Xiaowei Xu, Drew A Torigian, et al.
Cancer Medicine|June 1, 2021
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014Aman Opneja, Gino Cioffi, Asrar Alahmadi, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2012
Rehabilitation for oncogene addiction: role of immunity in cellular sobrietyDavid L Bajor, Robert H Vonderheide
Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2016
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after ChemotherapyKatelyn T Byrne, Nathan H Leisenring, David L Bajor, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|October 2, 2020
A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissuesYicheng Chen, Yiqing Zhao, David L Bajor, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
CD40 immunotherapy for pancreatic cancerRobert H Vonderheide, David L Bajor, Rafael Winograd, et al.
JCO Oncology Practice|January 12, 2021
Videoconference Intervention for Distance Caregivers of Patients With Cancer: A Randomized Controlled TrialSara L Douglas, Polly Mazanec, Amy R Lipson, et al.
Journal of Gastrointestinal Oncology|July 23, 2021
A pilot study of a low glycemic load diet in patients with stage I-III colorectal cancerMichelle Treasure, Alicia Thomas, Stephen Ganocy, et al.
Oncotarget|October 5, 2020
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?Erryk S Katayama, Jonathan J Hue, David L Bajor, et al.
Nature Communications|September 16, 2016
Metastatic progression is associated with dynamic changes in the local microenvironmentNicole M Aiello, David L Bajor, Robert J Norgard, et al.
Cancer Immunology Research|September 26, 2014
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanomaDavid L Bajor, Xiaowei Xu, Drew A Torigian, et al.
Cancer Medicine|June 1, 2021
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014Aman Opneja, Gino Cioffi, Asrar Alahmadi, et al.
Pageof 3